PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02189330
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
- Conditions
- Early Breast Cancer
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 226
- Registration Number
- NCT02187744
- Locations
- 🇷🇺
Saint-Peterbsurg Clinical Oncological dispensary of Moscow district, Saint-Petersburg, Russian Federation
🇷🇺LLC RAMSAY Diagnostic RUS, Saint-Petersburg, Russian Federation
🇷🇸Institute For Oncology And Radiology Of Serbia, Belgrade, Serbia
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
- Conditions
- Rhematoid Arthritis
- Interventions
- Biological: Adalimumab with methotrexate
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1152
- Registration Number
- NCT02187055
- Locations
- 🇺🇸
Ochsner Clinic Baton Rouge, Baton Rouge, Louisiana, United States
🇺🇸Centre for Rheumatology, Immunology and Arthritis, Fort Lauderdale, Florida, United States
🇺🇸Houston Institute For Clinical Research, Houston, Texas, United States
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line
- Conditions
- Metastatic/Advanced Renal Cell Carcinoma
- Interventions
- Other: Best supportive careOther: call center
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT02187042
- Locations
- 🇫🇷
CHU Strasbourg, Strasbourg, Cedex, France
🇫🇷Clinique Claude Bernard Chimiotherapie Ambulatoire, Metz, France
🇫🇷CRLC Val d'Aurelle, Montpellier cedex 05, France
Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT02187029
- Locations
- 🇺🇸
Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States
🇺🇸MRA Clinical Research, LLC, Miami, Florida, United States
🇺🇸Vince and Associates Clinical Research Inc., Overland Park, Kansas, United States
A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT02184429
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
- Conditions
- Metastatic Renal Cell Carcinoma (mRCC)
- Interventions
- Other: observational
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 573
- Registration Number
- NCT02184416
- Locations
- 🇳🇱
Viecuri Medical Centre, BL Venlo, Netherlands
🇦🇹Landeskrankenhaus Bregenz, Bregenz, Austria
🇦🇹Krankenhaus Oberwart, Oberwart, Austria
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT02179918
- Locations
- 🇺🇸
Research Administration Office, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States
🇺🇸UCLA Hematology-Oncology Clinic, Los Angeles, California, United States
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 172
- Registration Number
- NCT02175121
- Locations
- 🇺🇸
Compass Research, LLC, Orlando, Florida, United States
🇺🇸Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
🇺🇸Rainier Clinical Research Center, Inc., Renton, Washington, United States
A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02170012
- Locations
- 🇺🇸
MRA Clinical Research, LLC, South Miami, Florida, United States
🇺🇸Miami Research Associates, Inc., South Miami, Florida, United States